News

News

Amgen Challenges Opdivo® / Yervoy® Combination Treatment Patents in Three IPRs

by Robert S. Schwartz, Ph.D.
March 4, 2025

On February 28, 2025, Amgen filed three IPRs against Bristol-Myers Squibb’s patents covering methods of treatment using a combination of Opdivo® (nivolumab), an anti-PD-1 antibody, and Yervoy® (ipilimumab), an anti-CTLA-4 antibody: IPR2025-00601 challenging U.S. Patent No. 9,856,320, IPR2025-00602 challenging U.S. Patent No. 10,174,113, and IPR2025-00603 challenging U.S. Patent No. 11,332,529.  Amgen is currently conducting Phase III trials for ABP 206, an investigational biosimilar of Opdivo®.  These are the first patents related to Opdivo® that have been challenged by a potential biosimilar competitor.

On December 27, 2024, the FDA approved a subcutaneous version of Opdivo® called Opdivo Qvantig™ (nivolumab; hyaluronidase-nvhy).

Bristol-Myers Squibb reported U.S. sales of $5.35B for Opdivo® in 2024.

For more information about these and other biosimilars and biosimilar disputes, please visit BiologicsHQ.

 

_____________________________________________________

The author would like to thank April Breyer Menon for her contributions to this article.

    Methodology

    Information contained in the Venable BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book or on the FDA website (www.fda.gov). Information relating to FDA licensed products, FDA-approved indications, and aBLA and 505(b)(2) applications is obtained from public sources including the U.S. FDA website (www.fda.gov). Information relating to litigations is given only for cases active from January 31, 2010 onward. Information relating to foreign biosimilar / biologics follow-on products approved in Australia, Canada, the E.U., Japan and South Korea is from public sources. Statistics graphics are compiled from information contained in the Venable BiologicsHQ database.

    Disclaimer

    The individuals who maintain this site work for Venable LLP. The information, comments and links posted on this site do not constitute legal advice. No attorney-client relationship has been or will be formed by any communication(s) to, from or with the site and/or the author. For legal advice, contact an attorney at Venable LLP or an attorney actively practicing in your jurisdiction. Do not send any confidential or privileged information to the author; neither Venable LLP nor the author will assume any liability or responsibility for it. If you send any information, documents or materials to the site, you give permission for the author to include them on or in the site. No information, documents or materials you send to the site will be considered confidential or privileged by Venable LLP or its lawyers. Also, no such information, documents or materials will be returned to you. All decisions relating to the content belong to the author.

    Subscribe for Future Updates

      captcha